» Articles » PMID: 26976597

Human Mesenchymal Stromal Cells Reduce Influenza A H5N1-associated Acute Lung Injury in Vitro and in Vivo

Abstract

Influenza can cause acute lung injury. Because immune responses often play a role, antivirals may not ensure a successful outcome. To identify pathogenic mechanisms and potential adjunctive therapeutic options, we compared the extent to which avian influenza A/H5N1 virus and seasonal influenza A/H1N1 virus impair alveolar fluid clearance and protein permeability in an in vitro model of acute lung injury, defined the role of virus-induced soluble mediators in these injury effects, and demonstrated that the effects are prevented or reduced by bone marrow-derived multipotent mesenchymal stromal cells. We verified the in vivo relevance of these findings in mice experimentally infected with influenza A/H5N1. We found that, in vitro, the alveolar epithelium's protein permeability and fluid clearance were dysregulated by soluble immune mediators released upon infection with avian (A/Hong Kong/483/97, H5N1) but not seasonal (A/Hong Kong/54/98, H1N1) influenza virus. The reduced alveolar fluid transport associated with down-regulation of sodium and chloride transporters was prevented or reduced by coculture with mesenchymal stromal cells. In vivo, treatment of aged H5N1-infected mice with mesenchymal stromal cells increased their likelihood of survival. We conclude that mesenchymal stromal cells significantly reduce the impairment of alveolar fluid clearance induced by A/H5N1 infection in vitro and prevent or reduce A/H5N1-associated acute lung injury in vivo. This potential adjunctive therapy for severe influenza-induced lung disease warrants rapid clinical investigation.

Citing Articles

Mesenchymal stem cells and their extracellular vesicle therapy for neurological disorders: traumatic brain injury and beyond.

Yarahmadi A, Dorri Giv M, Hosseininejad R, Rezaie A, Mohammadi N, Afkhami H Front Neurol. 2025; 16:1472679.

PMID: 39974358 PMC: 11835705. DOI: 10.3389/fneur.2025.1472679.


Spinal cord injury enhances lung inflammation and exacerbates immune response following exposure to LPS.

Berk B, Pereira A, Vizcarra V, Proschel C, Hsu C Front Immunol. 2025; 15:1483402.

PMID: 39882237 PMC: 11774706. DOI: 10.3389/fimmu.2024.1483402.


Cell therapies for viral diseases: a new frontier.

Nardo D, Maddox E, Riley J Semin Immunopathol. 2025; 47(1):5.

PMID: 39747475 PMC: 11695571. DOI: 10.1007/s00281-024-01031-8.


miRNA-431-5p enriched in EVs derived from IFN-β stimulated MSCs potently inhibited ZIKV through CD95 downregulation.

Yuan M, Tian X, Ma W, Zhang R, Zou X, Jin Y Stem Cell Res Ther. 2024; 15(1):435.

PMID: 39563434 PMC: 11575116. DOI: 10.1186/s13287-024-04040-4.


Recent progress in mesenchymal stem cell-based therapy for acute lung injury.

Liang J, Dai W, Xue S, Wu F, Cui E, Pan R Cell Tissue Bank. 2024; 25(2):677-684.

PMID: 38466563 DOI: 10.1007/s10561-024-10129-0.


References
1.
Kunzelmann K, Beesley A, King N, Karupiah G, Young J, Cook D . Influenza virus inhibits amiloride-sensitive Na+ channels in respiratory epithelia. Proc Natl Acad Sci U S A. 2000; 97(18):10282-7. PMC: 27875. DOI: 10.1073/pnas.160041997. View

2.
Tsui P, Kwok M, Yuen H, Lai S . Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis. 2003; 9(9):1064-9. PMC: 3016795. DOI: 10.3201/eid0909.030362. View

3.
Elia N, Tapponnier M, Matthay M, Hamacher J, Pache J, Brundler M . Functional identification of the alveolar edema reabsorption activity of murine tumor necrosis factor-alpha. Am J Respir Crit Care Med. 2003; 168(9):1043-50. DOI: 10.1164/rccm.200206-618OC. View

4.
Leung C, Chiu W . Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children. Paediatr Respir Rev. 2004; 5(4):275-88. PMC: 7106106. DOI: 10.1016/j.prrv.2004.07.010. View

5.
Roberts A, Paddock C, Vogel L, Butler E, Zaki S, Subbarao K . Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol. 2005; 79(9):5833-8. PMC: 1082763. DOI: 10.1128/JVI.79.9.5833-5838.2005. View